Can you provide the average price target for RADIAN GROUP INC stock?
9 analysts have analysed RDN and the average price target is 37.41 USD. This implies a price increase of 5.54% is expected in the next year compared to the current price of 35.45.
NYSE:RDN • US7502361014
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RADIAN GROUP INC (RDN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-10 | Keefe, Bruyette & Woods | Maintains | Outperform -> Outperform |
| 2026-04-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-03-12 | UBS | Maintains | Neutral -> Neutral |
| 2026-02-11 | Keefe, Bruyette & Woods | Upgrade | Market Perform -> Outperform |
| 2026-01-02 | Roth Capital | Reiterate | Buy -> Buy |
| 2025-12-18 | Keefe, Bruyette & Woods | Maintains | Market Perform -> Market Perform |
| 2025-10-15 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-14 | UBS | Maintains | Neutral -> Neutral |
| 2025-07-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-07-07 | Keefe, Bruyette & Woods | Downgrade | Outperform -> Market Perform |
| 2025-05-23 | Compass Point | Downgrade | Buy -> Neutral |
| 2025-05-05 | UBS | Maintains | Neutral -> Neutral |
| 2025-05-02 | Keefe, Bruyette & Woods | Reiterate | Outperform -> Outperform |
| 2025-04-08 | Keefe, Bruyette & Woods | Maintains | Outperform -> Outperform |
| 2025-02-19 | UBS | Maintains | Neutral -> Neutral |
| 2025-01-08 | Keefe, Bruyette & Woods | Maintains | Outperform -> Outperform |
| 2024-10-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-08-05 | Keefe, Bruyette & Woods | Maintains | Outperform -> Outperform |
| 2024-08-02 | Roth MKM | Maintains | Buy -> Buy |
| 2024-08-02 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-08-02 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-06-03 | Keefe, Bruyette & Woods | Upgrade | Market Perform -> Outperform |
| 2024-05-22 | UBS | Maintains | Neutral -> Neutral |
| 2024-04-04 | Keefe, Bruyette & Woods | Downgrade | Outperform -> Market Perform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.241B 4.19% | 1.29B 4.01% | 1.198B -7.13% | 982.83M -17.98% | 1.009B 2.66% | 1.058B 4.86% | |
| EBITDA YoY % growth | 1.023B -9.36% | 1.026B 0.30% | 917.609M -10.57% | N/A | N/A | N/A | |
| EBIT YoY % growth | 943.881M -10.28% | 947.269M 0.36% | 871.175M -8.03% | 688.21M -21.00% | 780.28M 13.38% | N/A | |
| Operating Margin | 76.08% | 73.42% | 72.70% | 70.02% | 77.33% | N/A | |
| EPS YoY % growth | 3.89 -20.45% | 4.14 6.43% | 4.26 2.90% | 4.98 16.93% | 5.40 8.41% | 5.63 4.18% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.24 25.14% | 1.27 26.17% | 1.24 11.87% | 1.31 13.73% | 1.31 5.49% | 1.36 6.72% | 1.35 8.38% | 1.38 5.41% | 1.33 2.01% | 1.35 -0.48% | 1.38 2.81% | 1.43 4.03% |
| Revenue Q2Q % growth | 241.79M 2.16% | 244.42M 2.91% | 247.75M 4.49% | 247.96M 4.54% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 156.25M -26.16% | 172.61M -13.51% | 175.74M -21.93% | 187.66M -15.21% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
9 analysts have analysed RDN and the average price target is 37.41 USD. This implies a price increase of 5.54% is expected in the next year compared to the current price of 35.45.
RADIAN GROUP INC (RDN) will report earnings on 2026-05-06, after the market close.
The consensus EPS estimate for the next earnings of RADIAN GROUP INC (RDN) is 1.24 USD and the consensus revenue estimate is 241.79M USD.
The consensus rating for RADIAN GROUP INC (RDN) is 71.1111 / 100 . This indicates that analysts generally have a positive outlook on the stock.